newsfilter
← Latest News
ClinicalTrials.gov·

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants - NCT05780645

Maximum Observed Plasma Concentration (Cmax) of ALXN2050, Time to Reach Cmax (Tmax) of ALXN2050, Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of Last Measurable Concentration (AUC0-last) of ALXN2050, Number of Participants With Adverse Events (AEs)